Loss of FOXF1 expression promotes human lung-resident mesenchymal stromal cell migration via ATX/LPA/LPA1 signaling axis.
Animals
Binding Sites
/ genetics
Cell Movement
/ genetics
Cell Proliferation
/ genetics
Cells, Cultured
Chromatin Immunoprecipitation
Cytokines
/ metabolism
Forkhead Transcription Factors
/ genetics
Gene Ontology
Gene Silencing
Humans
Lung
/ cytology
Lysophospholipids
/ metabolism
Mesenchymal Stem Cells
/ metabolism
Mice
Phosphoric Diester Hydrolases
/ genetics
Promoter Regions, Genetic
RNA Interference
Receptors, Lysophosphatidic Acid
/ metabolism
Signal Transduction
/ genetics
Transcriptional Activation
/ genetics
Up-Regulation
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
04 12 2020
04 12 2020
Historique:
received:
25
03
2020
accepted:
09
11
2020
entrez:
5
12
2020
pubmed:
6
12
2020
medline:
15
4
2021
Statut:
epublish
Résumé
Forkhead box F1 (FOXF1) is a lung embryonic mesenchyme-associated transcription factor that demonstrates persistent expression into adulthood in mesenchymal stromal cells. However, its biologic function in human adult lung-resident mesenchymal stromal cells (LR-MSCs) remain to be elucidated. Here, we demonstrate that FOXF1 expression acts as a restraint on the migratory function of LR-MSCs via its role as a novel transcriptional repressor of autocrine motility-stimulating factor Autotaxin (ATX). Fibrotic human LR-MSCs demonstrated lower expression of FOXF1 mRNA and protein, compared to non-fibrotic controls. RNAi-mediated FOXF1 silencing in LR-MSCs was associated with upregulation of key genes regulating proliferation, migration, and inflammatory responses and significantly higher migration were confirmed in FOXF1-silenced LR-MSCs by Boyden chamber. ATX is a secreted lysophospholipase D largely responsible for extracellular lysophosphatidic acid (LPA) production, and was among the top ten upregulated genes upon Affymetrix analysis. FOXF1-silenced LR-MSCs demonstrated increased ATX activity, while mFoxf1 overexpression diminished ATX expression and activity. The FOXF1 silencing-induced increase in LR-MSC migration was abrogated by genetic and pharmacologic targeting of ATX and LPA1 receptor. Chromatin immunoprecipitation analyses identified three putative FOXF1 binding sites in the 1.5 kb ATX promoter which demonstrated transcriptional repression of ATX expression. Together these findings identify FOXF1 as a novel transcriptional repressor of ATX and demonstrate that loss of FOXF1 promotes LR-MSC migration via the ATX/LPA/LPA1 signaling axis.
Identifiants
pubmed: 33277571
doi: 10.1038/s41598-020-77601-1
pii: 10.1038/s41598-020-77601-1
pmc: PMC7718269
doi:
Substances chimiques
Cytokines
0
FOXF1 protein, human
0
Forkhead Transcription Factors
0
Lysophospholipids
0
Receptors, Lysophosphatidic Acid
0
Phosphoric Diester Hydrolases
EC 3.1.4.-
alkylglycerophosphoethanolamine phosphodiesterase
EC 3.1.4.39
lysophosphatidic acid
PG6M3969SG
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
21231Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL094622
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL118017
Pays : United States
Références
Biol Open. 2019 Feb 11;8(2):
pubmed: 30670377
Front Med (Lausanne). 2018 Jun 13;5:180
pubmed: 29951481
Bioinformatics. 2006 Jul 1;22(13):1600-7
pubmed: 16606683
Am J Pathol. 2011 Jun;178(6):2461-9
pubmed: 21641374
Stem Cells. 2012 Sep;30(9):2010-9
pubmed: 22782863
Mediators Inflamm. 2017;2017:9173090
pubmed: 29430083
Am J Respir Crit Care Med. 2011 Apr 15;183(8):1062-70
pubmed: 21169468
Am J Respir Crit Care Med. 2012 Jan 1;185(1):77-84
pubmed: 21940790
J Clin Invest. 2017 Apr 3;127(4):1517-1530
pubmed: 28240604
Am J Respir Cell Mol Biol. 2012 Nov;47(5):566-74
pubmed: 22744859
Oncogene. 2004 Mar 25;23(13):2357-66
pubmed: 14691447
Sci Rep. 2016 Mar 23;6:23433
pubmed: 27005960
Oncotarget. 2016 Jan 12;7(2):1912-26
pubmed: 26625197
Oncogene. 2005 Jul 28;24(32):5125-30
pubmed: 15897878
J Biol Chem. 2001 Jul 20;276(29):27488-97
pubmed: 11358962
Mol Cell Oncol. 2017 Mar 31;4(3):e1311827
pubmed: 28616586
Am J Physiol Lung Cell Mol Physiol. 2001 May;280(5):L823-38
pubmed: 11290504
Cell Stem Cell. 2014 Aug 7;15(2):123-38
pubmed: 25105578
Dev Biol. 2005 Mar 15;279(2):462-80
pubmed: 15733672
J Biol Chem. 2013 Oct 4;288(40):28477-87
pubmed: 23946491
J Immunol. 2014 Feb 1;192(3):851-7
pubmed: 24443508
Bioinformatics. 2007 Jan 15;23(2):257-8
pubmed: 17098774
Onco Targets Ther. 2016 Mar 23;9:1743-52
pubmed: 27042124
Am J Pathol. 2008 Nov;173(5):1566-76
pubmed: 18818380
Oncogene. 2017 Feb 9;36(6):850-862
pubmed: 27425595
Sci Signal. 2016 May 10;9(427):ra48
pubmed: 27165781
J Immunol. 2008 Sep 15;181(6):4389-96
pubmed: 18768898
Dev Biol. 1998 Oct 15;202(2):183-95
pubmed: 9769171
J Biol Chem. 1996 Feb 23;271(8):4482-90
pubmed: 8626802
BMC Bioinformatics. 2006 May 19;7:261
pubmed: 16712727
Behav Brain Res. 2001 Nov 1;125(1-2):279-84
pubmed: 11682119
Development. 2001 Jun;128(12):2397-406
pubmed: 11493558
Sci Rep. 2019 May 15;9(1):7414
pubmed: 31092842
Nucleic Acids Res. 2005 Nov 30;33(21):6782-94
pubmed: 16321965
J Lipid Res. 2014 Jun;55(6):1010-8
pubmed: 24548887
Genes Dev. 2014 Jun 15;28(12):1363-79
pubmed: 24939938
Cell Rep. 2018 Apr 10;23(2):442-458
pubmed: 29642003
Cell Stem Cell. 2017 Aug 3;21(2):166-177
pubmed: 28777943
Cell Cycle. 2009 Nov 15;8(22):3695-701
pubmed: 19855166
EMBO J. 1994 Oct 17;13(20):5002-12
pubmed: 7957066
J Clin Invest. 2007 Apr;117(4):989-96
pubmed: 17347686
Stat Appl Genet Mol Biol. 2004;3:Article3
pubmed: 16646809
Blood. 2014 Nov 13;124(20):3141-50
pubmed: 25277122
PLoS Genet. 2017 Aug 10;13(8):e1006951
pubmed: 28797033
Oncogene. 2014 Oct 2;33(40):4837-46
pubmed: 24186199